GlaxoSmithKline, which has operations in Upper Merion, has reported a strong immune response in adults aged 65 and older from its shingles vaccine Shingrix, writes Linda Loyd for Philly.com.

The study’s participants had previously been vaccinated for Shingles with Merck’s Zostavax. However, research has shown that the effectiveness of Merck’s vaccine wanes over time. With its new vaccine, GSK is looking to provide longer-term protection.

.

Research had also raised the question of whether people already vaccinated by Zostavax, can then receive GSK’s vaccine.

“The answer is yes,” said Leonard Friedland, GSK director of scientific affairs and public health for vaccines. “Our data show that you can do it safely and effectively.”

GSK presented the results last week at a meeting with the Center for Disease Control and Prevention in Atlanta. They showed that the 430 adults who were vaccinated with Merck’s shingles vaccine five years ago and now revaccinated with GSK’s Shingrix, showed no serious side effects.

GSK has already filed for regulatory approval from the FDA to commercialize Shingrix. A decision is expected by the end of the year.

Read more about GSK’s Shingrix at Philly.com by clicking here.

_______

Top photo credit: Radio Alfa Vaccine via photopin (license)